Track record · closed signal

Pfizer Inc. (PFE) — closed signal from January 3, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on April 3, 2026.

Predicted vs. what happened

PFE price · publication thesis → realized outcomesplit-adjusted

$24.60 – $25.50Entry zone — fair-value band

$25.18Published — price the day we called it

$28.20Target — the price the thesis aimed for

$28.75Peak — highest point inside the window, not a realized return

$28.32Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 87 days.

Peak price

$28.75

peak on April 2, 2026 — not a realized return

Peak gain

+14.2%

peak, from the publication price

Window close

$28.32

end-of-window price, context only

Days to target

Window

January 3, 2026 – April 3, 2026

The thesis — published January 3, 2026

Predicted growth

+12%

over the measurement window

Target price

$28.20

the price the thesis aimed for

Entry zone

$24.60 – $25.50

the fair-value band we waited for

Price at publication

$25.18

published January 3, 2026

Confidence

69%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

This is a short-term trade idea: Pfizer looks very oversold so a bounce is likely in the next few weeks. Their strong cash flow makes the dividend seem safe, and an analyst target of $30 gives a clear upside math. Because the company has some longer-term risks, this is a price-driven swing trade rather than a bet the business will be revalued higher.

Primary drivers

Stock looks unusually low and may bounce soon
Strong cash flow makes the dividend feel safer
Cost cutting and focused drug pipeline support outlook
Analyst $30 target gives clear near-term upside

How it played out

PFE: target reached in 87 days

Lyra published PFE at $25.18 on January 3, 2026, as a short-term swing trade with 12% expected growth. The thesis pointed to an unusually low stock price, a possible bounce, strong cash flow supporting the dividend, cost cutting, a focused drug pipeline, and an analyst target of $30.

Inside the window, PFE rose to a peak of $28.75 on April 2, 2026. It reached the $28.20 target in 87 days. The stock ended the window at $28.32, still above the target. The published thesis played out.

What happened during the window

On February 3, 2026, Pfizer reported fourth-quarter 2025 sales of $17.56 billion and adjusted earnings of 66 cents a share. The company also reiterated its 2026 revenue guidance of $59.5 billion to $62.5 billion. MarketWatch reported the same day that Pfizer released midstage data for PF-3944, with 10% and 12.3% weight reductions over 28 weeks.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All PFE signals